These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 5395537)
1. Absorption and urinary excretion of oxyphencyclimine HCl in patients before and after a prolonged oxyphencyclimine treatment. Mózsik G; Berstad A; Myren J; Setekleiv J Med Exp Int J Exp Med; 1969; 19(1):10-6. PubMed ID: 5395537 [No Abstract] [Full Text] [Related]
2. [The gastric secretion before and after treatment with oxyphencyclimine HC1 (Daricon)]. Myren J; Burhol PG Tidsskr Nor Laegeforen; 1967 Oct; 87(19):1607-9. PubMed ID: 5628489 [No Abstract] [Full Text] [Related]
3. Distribution of tritiated cyclandelate (3,5,5-trimethylcyclohexyl mandelate)-a vasoactive drug: preliminary observations by liquid scintillation spectrometry. Orr A; Whittier JR Int J Nucl Med Biol; 1974 Jun; 1(4):205-13. PubMed ID: 4435997 [No Abstract] [Full Text] [Related]
4. A study of the selectivity of action of oxyphencyclimine hydrochloride on gastric secretion. (selectivity of oxyphencyclimine). Herrmann RP; Sulway MJ Curr Ther Res Clin Exp; 1973 Jun; 15(6):291-7. PubMed ID: 4197253 [No Abstract] [Full Text] [Related]
5. Studies on the metabolic fate and the pharmacokinetics of 5-n-butyl-1-cyclohexyl-2,4,6-trioxoperhydropyrimidine (BCP) in man. II. Determination of BCP and its metabolite, 1-cyclohexyl-5-(3-hydroxybutyl)-2,4,6-trioxoperhydropyrimidine by ultraviolet absorption method. Yashiki T; Kondo T; Uda Y; Mima H Chem Pharm Bull (Tokyo); 1971 Mar; 19(3):478-86. PubMed ID: 5553047 [No Abstract] [Full Text] [Related]
6. Studies on the metabolic fate and the pharmacokinetics of 5-n-butyl-1-cyclohexyl-2,4,6-trioxoperhydropyrimidine (BCP) in man. 3. Gas-liquid chromatographic determination of BCP and its metabolites. Yashiki T; Uda Y; Kondo T; Mima H Chem Pharm Bull (Tokyo); 1971 Mar; 19(3):487-92. PubMed ID: 5553048 [No Abstract] [Full Text] [Related]
7. Studies on the metabolic fate and the pharmacokinetics of 5-n-butyl-1-cyclohexyl-2,4,6-trioxoperhydropyrimidine (BCP) in man. I. Identification of the metabolites of BCP in human urine. Yashiki T; Matsuzawa T; Kondo T; Uda Y; Shima T Chem Pharm Bull (Tokyo); 1971 Mar; 19(3):468-77. PubMed ID: 5553046 [No Abstract] [Full Text] [Related]
8. Metabolism in the human of 3, 4-dihydroxymandelic acid, one of the metabolites of noradrenaline and adrenaline. Goodall M; Alton H Biochem Pharmacol; 1969 Feb; 18(2):295-302. PubMed ID: 5778148 [No Abstract] [Full Text] [Related]
9. [Anticholinergic effect of tropenzilinium and oxyphencyclimine]. Pantio M; Saarimaa H; Strandman D Lakartidningen; 1971 Aug; 68(32):3558-9. PubMed ID: 5166569 [No Abstract] [Full Text] [Related]
10. Oxyphencyclimine and oxyphencyclimine-hydroxyzine. Effects on human gastric secretion and use in treatment of peptic ulcer and related disorders. RIDER JA; MOELLER HC; OLIVARES-AGCAOILI L Am Pract Dig Treat; 1962 Sep; 13():591-7. PubMed ID: 14492109 [No Abstract] [Full Text] [Related]
11. Kinetics of urinary excretion of D-(minus)-mandelic acid and its homologs. II. Competitive inhibitory effect of D-(minus)-mandelic acid and DL-tropic acid on their renal tubular secretion in rats. Randinitis EJ; Barr M; Nagwekar JB J Pharm Sci; 1970 Jun; 59(6):813-8. PubMed ID: 5423084 [No Abstract] [Full Text] [Related]
12. The effect of prolonged glucagon infusions on the urinary excretion of catecholamines and 4-hydroxy-3-methoxymandelic acid and on adrenal medullary tissue levels of catecholamines in patients with severe cardiac disease. Hinterberger H; Wilcken DE Clin Chim Acta; 1974 Apr; 52(2):153-61. PubMed ID: 4828228 [No Abstract] [Full Text] [Related]
13. Parasympatholytic agents in duodenal ulcer. Double-blind controlled trial with oxyphencyclimine hydrochloride. Goyal RK; Bhardwaj OP; Chuttani HK J Indian Med Assoc; 1968 Apr; 50(8):365-7. PubMed ID: 4874902 [No Abstract] [Full Text] [Related]
14. Effect of alcohol on the kinetics of mandelic acid excretion in volunteers exposed to styrene vapour. Wilson HK; Robertson SM; Waldron HA; Gompertz D Br J Ind Med; 1983 Feb; 40(1):75-80. PubMed ID: 6824604 [TBL] [Abstract][Full Text] [Related]
15. [Observations on the use of an new pharmacologic association with anticholinergic-sedative action (oxyphencyclimine-promazine)]. Mioli V G Clin Med; 1965 Jan; 46(1):54-72. PubMed ID: 5892935 [No Abstract] [Full Text] [Related]
16. [The use of the combination of oxyphencyclimine and meprobamate in peptic ulcer]. FISCHMAN S Sem Med; 1962 Oct; 121():1650-3. PubMed ID: 13963059 [No Abstract] [Full Text] [Related]
17. [Pharmacokinetics and metabolism of 3H-synephrine (author's transl)]. Hengstmann JH; Aulepp H Arzneimittelforschung; 1978; 28(12):2326-31. PubMed ID: 582950 [TBL] [Abstract][Full Text] [Related]
18. [Correlations between urinary excretion of 4-hydroxy-3-methoxy-mandelic acid and catecholamines in cardiac failure]. Valori C; Brunori CA; Renzini V; Alicandri C Cuore Circ; 1968 Feb; 52(1):41-56. PubMed ID: 5744982 [No Abstract] [Full Text] [Related]
19. Mutual inhibitory effect of (-)-mandelic acid and certain sulfonamides on the kinetics of their urinary excretion in humans. Kamienny FM; Barr M; Nagwekar JB J Pharm Sci; 1969 Nov; 58(11):1318-24. PubMed ID: 5349742 [No Abstract] [Full Text] [Related]
20. [24-hour excretion of 5-hydroxyindoleacetic acid and 3-methoxy-4-hydroxymandelic acid in patients with partial gastrectomy for peptic ulcer]. Knapik Z; Lubczyńska-Kowalska W; Wrzyscz M; Brablec-Radek J; Cader J Pol Tyg Lek; 1973 Jan; 28(5):168-71. PubMed ID: 4689197 [No Abstract] [Full Text] [Related] [Next] [New Search]